Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I weekly intravenous JR-441 in pediatric patients with mucopolysaccharidosis type IIIA
jRCT2071240053Phase 1Active, not recruiting
- Sponsor
- JCR Pharmaceuticals
- Start
- Oct 2024
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of posnafusp alfa in mucopolysaccharidosis type III A (3 arms), sponsored by JCR Pharmaceuticals. Primary endpoints: Incidence and severity of treatment-emergent adverse events, Change in safety laboratory tests and 2 more. Started Oct 2024; status: active, not recruiting.
02
Drugs
posnafusp alfa
03
Conditions
mucopolysaccharidosis type III A
Beyond the preview
Go deeper on jRCT2071240053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240053.